Preoperative chemotherapy for breast cancer: Lessons learned and future prospects

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4481-4482

  Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; TAXANE DERIVATIVE; TRASTUZUMAB; AC PROTOCOL; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MICROARRAY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; MASTECTOMY; NOTE; PATHOLOGY; PREOPERATIVE CARE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 1542648387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.980     Document Type: Editorial

References (12)

1. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
2. van der Hage J, van de Velde C, Julien J-P, et al: Preoperative chemotherapy in primary breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19:4224-4237, 2001
3. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
4. Fisher E, Wang JQ, Bryant J, et al: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681-695, 2002
5. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046, 2002
6. Heys S: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3:69-74, 2002 (suppl 2)
7. Citron M, Berry D, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
8. Miller K, McCaskill-Stevens W, Sisk J, et al: Combination versus sequential doxorubicin and taxotere as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999
9. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
10. Burstein H, Harris L, Kaelin C, et al: Preoperative Herceptin and paclitaxel for HER-2 overexpressing stage I/II breast cancer. Proc Am Soc Clin Oncol 20:26, 2001 (abstr 100)
11. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
12. Ayers M, Symmans W, Stec J, et al: Gene expression profiling of fine needle aspirates of breast cancer identifies genes associated with complete pathologic response to neoadjuvant taxol/FAC chemotherapy. Breast Cancer Res Treat 76:64, 2002